| APCs | antigen-presenting cells |
| BEDs | biologically effective doses |
| CTL | cytotoxic T cells |
| CTLA-4 | cytotoxic T cell-associated antigen 4 |
| CSF-1R | colony-stimulating factor 1 receptor |
| DAMP | damage-associated molecular patterns |
| DC | dendritic cells |
| DSBs | double-strand breaks |
| GM-CSF | granulocyte colony-stimulating factor |
| ICD | immunogenic cell death |
| ICI | immune checkpoint inhibitor |
| IFN | Interferon |
| LC | local control |
| LF | local failure |
| MDSCs | myeloid-derived suppressor cells |
| MHC | major histocompatibility complex |
| NK | natural killer |
| NSCLC | non-small cell lung cancer |
| PD-1 | programmed cell death protein 1 |
| PD-L1 | programmed cell death-ligand 1 |
| PFS | progression-free survival |
| RT | Radiation therapy |
| SRT | stereotactic radiation therapy |
| SRS | Radiosurgery |
| SBRT | stereotactic body radiation therapy |
| TAA | tumor-associated antigen |
| TAMs | tumor-associated macrophage |
| TCR | T cell receptor |
| TILs | tumor-infiltrating lymphocytes |
| TME | tumor microenvironment |